Published :
Tables : 52
Figures : 47
Category : Healthcare
No. of Pages : 233
Report Code : HC-1091
Liquid Biopsy Market Overview: Liquid biopsy market is anticipated to value over USD 3.38 billion by the end of 2027 and expanding at a CAGR of over 23.7% during the forecast period, 2020 to 2027. Liquid biopsy tests are executed to understand the molecular aspects of cancer across the healthcare and research settings, such as hospitals, physicians, pathological and research laboratories. It is a non-invasive blood test that could provide researchers, physicians, and surgeons with information about the cancer profile of the patient and appropriate therapy to improve the survival rate of cancer patients. It is a rapid process that usually includes a simple blood draw, extraction of nucleic acids from the blood plasma, and amplification of the molecular targets to permit analysis of the defined biomarkers. Easy and non-invasive access to the tumour genome, early cancer diagnosis & detection, characterization of new lesions, drug & therapeutic target identifications for cancer treatment are some advantages of liquid biopsies, which improve the safety and efficiency of cancer therapy for patients. Increasing importance of non-invasive surgical techniques led to the rapid adoption of liquid biopsy in primary healthcare settings. Liquid biopsy is used for detection of epidermal growth factor receptor mutations and it appears in 10 to 35% of non-small cell lung cancer. Increasing prevalence of non-small cell lung cancer led to the robust growth of the market. According to the American Cancer Society, about 80-85% of lung cancer is non-small cell lung cancer and they are 228,150 newly diagnosed cases of lung cancer in 2019. Further, the rapid advancement of technologies augmented the existing technologies and led to the development of simple equipment. Along with this, increasing R&D investments in strengthening existing portfolios fuelled the growth of the market. Developing economies like North America and Europe regions accounts more than 60% share of the global market. North America accounts major share in the global market due to high adoption. It is followed by Europe and it is majorly dominated by the UK, Germany, and France. Developing economies like the Asia Pacific and Latin America is the most opportunistic market space for manufacturers due to a limited number of manufacturers in these regions. These regions are expected to witness the highest growth rate during the forecast period. Rest of world accounts small fraction in the global market and it has the limited presence of manufacturers Liquid Biopsy market players include: Biocept, Inc, Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc, Menarini-Silicon Biosystems, Trovagene Inc., Guardant Health, Inc., Mdxhealth SA, Genomic Health Inc. Liquid Biopsy Market Segmentation: By Product Assays Kits Instruments Services By Circulating Biomarker Circulating Tumor Cells (CTCs) Circulating Tumor DNA (ctDNA) Cell-Free DNA (cfDNA) Extracellular Vesicles (EVs) Other Circulating Biomarkers By Clinical Application Early Cancer Screening Therapy Selection Treatment Monitoring Recurrence Monitoring Orthopedics By Application • Oncology o Lung Cancer o Breast Cancer o Colorectal Cancer o Prostate Cancer o Melanoma Cancer o Other Cancers • Non-Cancer Application By End User Reference Laboratories Hospitals and Physician Laboratories Academic and Research Centers Other End Users By Region North America Latin America Europe Asia Pacific Rest of the World Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global Liquid Biopsy Market by product, by circulating biomarker, by clinical application, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Liquid biopsy market is anticipated to value over USD 3.38 billion by the end of 2027 and expanding at a CAGR of over 23.7% during the forecast period, 2020 to 2027.
Liquid biopsy tests are executed to understand the molecular aspects of cancer across the healthcare and research settings, such as hospitals, physicians, pathological and research laboratories. It is a non-invasive blood test that could provide researchers, physicians, and surgeons with information about the cancer profile of the patient and appropriate therapy to improve the survival rate of cancer patients. It is a rapid process that usually includes a simple blood draw, extraction of nucleic acids from the blood plasma, and amplification of the molecular targets to permit analysis of the defined biomarkers. Easy and non-invasive access to the tumour genome, early cancer diagnosis & detection, characterization of new lesions, drug & therapeutic target identifications for cancer treatment are some advantages of liquid biopsies, which improve the safety and efficiency of cancer therapy for patients.
Increasing importance of non-invasive surgical techniques led to the rapid adoption of liquid biopsy in primary healthcare settings. Liquid biopsy is used for detection of epidermal growth factor receptor mutations and it appears in 10 to 35% of non-small cell lung cancer. Increasing prevalence of non-small cell lung cancer led to the robust growth of the market. According to the American Cancer Society, about 80-85% of lung cancer is non-small cell lung cancer and they are 228,150 newly diagnosed cases of lung cancer in 2019. Further, the rapid advancement of technologies augmented the existing technologies and led to the development of simple equipment. Along with this, increasing R&D investments in strengthening existing portfolios fuelled the growth of the market.
Developing economies like North America and Europe regions accounts more than 60% share of the global market. North America accounts major share in the global market due to high adoption. It is followed by Europe and it is majorly dominated by the UK, Germany, and France. Developing economies like the Asia Pacific and Latin America is the most opportunistic market space for manufacturers due to a limited number of manufacturers in these regions. These regions are expected to witness the highest growth rate during the forecast period. Rest of world accounts small fraction in the global market and it has the limited presence of manufacturers
Liquid Biopsy market players include:
Biocept, Inc, Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc, Menarini-Silicon Biosystems, Trovagene Inc., Guardant Health, Inc., Mdxhealth SA, Genomic Health Inc.
Liquid Biopsy Market Segmentation:
By Product
By Circulating Biomarker
By Clinical Application
By Application
• Oncology o Lung Cancer o Breast Cancer o Colorectal Cancer o Prostate Cancer o Melanoma Cancer o Other Cancers • Non-Cancer Application
By End User
By Region
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global Liquid Biopsy Market by product, by circulating biomarker, by clinical application, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Liquid Biopsy Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Liquid Biopsy Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Liquid Biopsy Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Liquid Biopsy Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Assays Kits 7.2. Instruments 7.3. Services 8. Global Liquid Biopsy Market, By Circulating Biomarker Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Circulating Tumor Cells (CTCs) 8.2. Circulating Tumor DNA (ctDNA) 8.3. Cell-Free DNA (cfDNA) 8.4. Extracellular Vesicles (EVs) 8.5. Other Circulating Biomarkers 9. Global Liquid Biopsy Market, By Clinical Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Early Cancer Screening 9.2. Therapy Selection 9.3. Treatment Monitoring 9.4. Recurrence Monitoring Orthopedics 10. Global Liquid Biopsy Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Oncology 10.1.1. Lung Cancer 10.1.2. Breast Cancer 10.1.3. Colorectal Cancer 10.1.4. Prostate Cancer 10.1.5. Melanoma Cancer 10.1.6. Other Cancers 10.2. Non-Cancer Application 11. Global Liquid Biopsy Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Reference Laboratories 11.2. Hospitals and Physician Laboratories 11.3. Academic and Research Centers 11.4. Other End Users 12. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028 13. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028 14. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Switzerland 14.2.9. Rest of Western Europe 15. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. Singapore 15.2.4. India 15.2.5. Australia and New Zealand 15.2.6. ASEAN 15.2.7. South Korea 15.2.8. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 17.1. Biocept, Inc 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Qiagen N.V. 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Roche Diagnostics 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Bio-Rad Laboratories, Inc. 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Myriad Genetics, Inc 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Menarini-Silicon Biosystems 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Trovagene, Inc. 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Guardant Health, Inc. 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Mdxhealth SA 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10. Genomic Health, Inc. 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME key takeaway points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics